[go: up one dir, main page]

PE20140123A1 - Formas cristalinas de la sal clorhidrato de (4a-r,9a-s)-1-(1h-benzoimidazol-5-carbonil)-2,3,4,4a,9,9a-hexahidro-1h-inden[2,1-b]piridin-6-carbonitrilo y su uso como inhibidores de hsd 1 - Google Patents

Formas cristalinas de la sal clorhidrato de (4a-r,9a-s)-1-(1h-benzoimidazol-5-carbonil)-2,3,4,4a,9,9a-hexahidro-1h-inden[2,1-b]piridin-6-carbonitrilo y su uso como inhibidores de hsd 1

Info

Publication number
PE20140123A1
PE20140123A1 PE2013000949A PE2013000949A PE20140123A1 PE 20140123 A1 PE20140123 A1 PE 20140123A1 PE 2013000949 A PE2013000949 A PE 2013000949A PE 2013000949 A PE2013000949 A PE 2013000949A PE 20140123 A1 PE20140123 A1 PE 20140123A1
Authority
PE
Peru
Prior art keywords
ppm
hsd
inden
carbonitrile
hexahydro
Prior art date
Application number
PE2013000949A
Other languages
English (en)
Inventor
Matthias Eckhardt
Hans-Juergen Martin
Martin Schuehle
Sandra Sick
Bing-Shiou Yang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140123(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2010/055586 external-priority patent/WO2011057054A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20140123A1 publication Critical patent/PE20140123A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A FORMAS CRISTALINAS DEL COMPUESTO DE FORMULA (II) QUE ES LA SAL CLORHIDRATO DE (4a-R,9a-S)-1-(1H-BENZOIMIDAZOL-5-CARBONIL)-2,3,4,4a,9,9a-HEXAHIDRO-1H-INDEN[2,1-b]PIRIDIN-6-CARBONITRILO, TALES COMO: A) LA FORMA CRISTALINA I CUYOS PICOS DE DIFRACCION DE RAYOS X EN POLVO A ANGULOS 2TETHA SON 12.5�, 12.9�, 14.8�, 20,0�, 22.2� Y 26.1�; Y CUYOS PICOS DE RESONANCIA MAGNETICA NUCLEAR 13C EN ESTADO SOLIDO SON 170.3 ppm, 146.5 ppm, 142.8 ppm, 135.0 ppm, 130.6 ppm, 128.1 ppm, 122.1 ppm, 116.7 ppm, ENTRE OTROS; Y B) LA FORMA CRISTALINA II CUYOS PICOS DE DIFRACCION DE RAYOS X EN POLVO A ANGULOS 2TETHA SON 13.7�, 17.6�, 19.7�, 21.3�, 21,9�, 23.3�, 25.6�, 26.5�, ENTRE OTROS; Y CUYOS PICOS DE RESONANCIA MAGNETICA NUCLEAR 13C EN ESTADO SOLIDO SON 172.6 ppm, 147.1 ppm, 144.1 ppm, 132.9 ppm, 129.6 ppm, 125.9 ppm, 121.2 ppm, 119.5 ppm, ENTRE OTROS. DICHO COMPUESTO ES INHIBIDOR DE LA ENZIMA 11B-HIDROXIESTEROIDE DESHIDROGENASA (HSD) 1 SIENDO UTIL EN EL TRATAMIENTO DE DIABETES TIPO 2, OBESIDAD, DISLIPIDEMIA
PE2013000949A 2010-11-05 2011-11-04 Formas cristalinas de la sal clorhidrato de (4a-r,9a-s)-1-(1h-benzoimidazol-5-carbonil)-2,3,4,4a,9,9a-hexahidro-1h-inden[2,1-b]piridin-6-carbonitrilo y su uso como inhibidores de hsd 1 PE20140123A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2010/055586 WO2011057054A1 (en) 2009-11-06 2010-11-05 Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
US201161484995P 2011-05-11 2011-05-11

Publications (1)

Publication Number Publication Date
PE20140123A1 true PE20140123A1 (es) 2014-03-02

Family

ID=44999935

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000949A PE20140123A1 (es) 2010-11-05 2011-11-04 Formas cristalinas de la sal clorhidrato de (4a-r,9a-s)-1-(1h-benzoimidazol-5-carbonil)-2,3,4,4a,9,9a-hexahidro-1h-inden[2,1-b]piridin-6-carbonitrilo y su uso como inhibidores de hsd 1

Country Status (36)

Country Link
US (2) US8686149B2 (es)
EP (1) EP2635563B1 (es)
JP (1) JP2013541592A (es)
KR (1) KR20130119939A (es)
CN (1) CN103228642B (es)
AP (1) AP3521A (es)
AR (1) AR083678A1 (es)
AU (1) AU2011323164B2 (es)
BR (1) BR112013011095A2 (es)
CA (1) CA2816136A1 (es)
CL (1) CL2013001221A1 (es)
CO (1) CO6781480A2 (es)
CY (1) CY1116043T1 (es)
DK (1) DK2635563T3 (es)
EA (1) EA022406B1 (es)
EC (2) ECSP12011788A (es)
ES (1) ES2533833T3 (es)
GE (1) GEP20166481B (es)
HR (1) HRP20150327T1 (es)
IL (1) IL225647A0 (es)
ME (1) ME02066B (es)
MX (1) MX2013005069A (es)
NZ (1) NZ609281A (es)
PE (1) PE20140123A1 (es)
PH (1) PH12013500879A1 (es)
PL (1) PL2635563T3 (es)
PT (1) PT2635563E (es)
RS (1) RS53900B1 (es)
SG (1) SG189859A1 (es)
SI (1) SI2635563T1 (es)
SM (1) SMT201500095B (es)
TN (1) TN2012000117A1 (es)
TW (1) TWI537258B (es)
UA (1) UA110807C2 (es)
UY (1) UY33701A (es)
WO (1) WO2012061708A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069545A1 (es) 2007-11-16 2010-02-03 Boehringer Ingelheim Pharma Derivados de aril y heteroarilcarbonilo de benzomorfanos y estructuras relacionadas, composiciones farmaceuticas que contienen dichos compuestos, obtencion de las mismas, su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa (hsd) 1 y
JP5711115B2 (ja) 2008-05-13 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンゾモルファン及び関連骨格のアリサイクリックカルボン酸誘導体、そのような化合物を含有する医薬及びその使用
JP5670440B2 (ja) 2009-06-02 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
WO2011159760A1 (en) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
TWI537258B (zh) 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
EP2744783A1 (en) 2011-08-17 2014-06-25 Boehringer Ingelheim International GmbH Indenopyridine derivatives
BR112014027884A2 (pt) * 2012-05-09 2017-06-27 Boehringer Ingelheim Int combinações farmacêuticas para tratamento de distúrbios metabólicos
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
CN113557235B (zh) 2019-03-06 2025-08-08 C4医药公司 用于药物治疗的杂环化合物
CN118005644B (zh) * 2024-01-29 2025-12-16 中国科学院南海海洋研究所 十氢芴型生物碱及其制备方法和在制备抗菌药物中应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127995C (es) 1963-12-20 Geigy Ag J R
US3341538A (en) 1965-06-18 1967-09-12 Geigy Chem Corp Certain 2, 6-methano-3-benzazocines
DE1785124A1 (de) 1968-08-13 1971-11-11 Prym Werke William Reissverschluss
DE2108954A1 (en) 1971-02-25 1972-09-07 Boehringer Sohn Ingelheim 2-(furylmethyl)-6,7-benzomorphans - useful as cns active agents
GB1304175A (es) 1969-03-31 1973-01-24
DE2105743C3 (de) 1971-02-08 1979-11-29 Boehringer Sohn Ingelheim 2-(Furylmethyl)- a -5,9-dialkyl -6,7benzomorphane, Verfahren zu ihrer Herstellung und deren Verwendung
US3681349A (en) 1970-03-05 1972-08-01 Morton Norwich Products Inc 1-(substituted benzyl) tetrahydro-2-(1h) pyrimidones
US3657257A (en) 1970-08-31 1972-04-18 Robins Co Inc A H 3-aryl-8-carbamoyl nortropanes
DE2229695A1 (de) 1972-06-19 1974-01-31 Boehringer Sohn Ingelheim 2-(heteroaryl-methyl)-5,9 beta-dialkyl6,7-benzomorphane, deren saeureadditionssalze sowie verfahren zu deren herstellung
DE2338369A1 (de) 1973-07-26 1975-02-13 Schering Ag Mikrobiologische hydroxylierung von 2,6-methano-3-benzazocinen
SU511005A3 (ru) 1973-10-27 1976-04-15 К.Х.Берингер Зон., (Фирма) Способ получени (метоксиметилфурилметил)6,7-бензоморфанов или морфинанов
US4009171A (en) 1974-02-21 1977-02-22 Sterling Drug Inc. N-acylated-11-oxygenated-2,6-methano-3-benzazocine intermediates
DE2411382C3 (de) 1974-03-09 1979-09-06 C.H. Boehringer Sohn, 6507 Ingelheim 2-Tetrahydrofurfuryl-6,7-benzomorphane, Verfahren zur Herstellung und deren Verwendung
US4087532A (en) 1974-03-09 1978-05-02 Boehringer Ingelheim Gmbh Analgesically useful 2-tetrahydrofurfuryl-5-lower alkyl-2-oxy-6,7-benzomorphans and salts thereof
DE2437610A1 (de) 1974-08-05 1976-02-26 Boehringer Sohn Ingelheim Neue 5,9-beta-disubstituierte 2-tetrahydrofurfuryl-6,7-benzomorphane, deren saeureadditionssalze, ihre verwendung als arzneimittel und verfahren zu deren herstellung
US4108857A (en) 1975-08-18 1978-08-22 Sterling Drug Inc. Imidazolylmethyl methanobenzazocines
DE2828039A1 (de) 1978-06-26 1980-01-10 Boehringer Sohn Ingelheim 2-(2-alkoxyethyl)-2'-hydroxy-6,7-benzomorphane deren saeureadditionssalze diese enthaltende arzneimittel und verfahren zu deren herstellung
GB9510459D0 (en) 1995-05-24 1995-07-19 Zeneca Ltd Bicyclic amines
GB9517622D0 (en) * 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
CA2262502C (en) 1996-07-31 2002-11-26 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same
GB9623944D0 (en) 1996-11-15 1997-01-08 Zeneca Ltd Bicyclic amine derivatives
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
WO2001055063A1 (en) 2000-01-25 2001-08-02 Idemitsu Petrochemical Co., Ltd. Novel bisadamantane compounds, process for preparing the same, and novel biadamantane derivatives
DE10034623A1 (de) 2000-07-17 2002-01-31 Bayer Ag Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren
AU2003234621A1 (en) 2002-05-17 2003-12-02 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1610789B1 (en) 2003-03-26 2010-07-21 Merck Sharp & Dohme Corp. Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
EP1615698B1 (en) * 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
EA011021B1 (ru) 2004-05-07 2008-12-30 Янссен Фармацевтика Н.В. Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AU2005279209B2 (en) 2004-08-30 2011-03-24 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-BETA hydroxysteroid dehydrogenase inhibitors
EP1802623A1 (en) 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
EP1809626A2 (en) 2004-10-13 2007-07-25 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
EP1864971A4 (en) 2005-03-31 2010-02-10 Takeda Pharmaceutical PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES
JP2009514818A (ja) 2005-11-01 2009-04-09 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換アミドの製薬学的用途
US8053431B2 (en) 2005-11-01 2011-11-08 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted amides
JP2007140188A (ja) 2005-11-18 2007-06-07 Fujifilm Corp ポジ型感光性組成物及びそれを用いたパターン形成方法
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2007081570A2 (en) 2005-12-30 2007-07-19 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
US20070197530A1 (en) 2006-01-31 2007-08-23 Yun-Long Li Amido compounds and their use as pharmaceuticals
CN101541747B (zh) 2006-04-21 2012-11-14 伊莱利利公司 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的联苯基酰胺内酰胺衍生物
DK2029529T3 (da) 2006-04-24 2010-09-20 Lilly Co Eli Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1
AU2007244861B2 (en) 2006-04-25 2012-03-15 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
TW200811170A (en) 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
US8132151B2 (en) 2006-07-18 2012-03-06 Yahoo! Inc. Action tags
BRPI0717657A2 (pt) 2006-10-19 2013-12-24 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, usos de compostos, métodos para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, displidemia e hipertensão e profilaxia de diabetes do tipo ii
TW200829171A (en) 2006-11-17 2008-07-16 Nihon Nohyaku Co Ltd Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
WO2008106128A2 (en) 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
EA200970841A1 (ru) 2007-03-09 2010-04-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтическое применение замещенных амидов
AR067673A1 (es) 2007-07-26 2009-10-21 Vitae Pharmaceuticals Inc Derivados de 1,3 oxazinan - 2 - ona como inhibidores ciclicos de la 11 beta -hidroxiesteroide deshidrogenasa 1. composiciones farmaceuticas.
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
AR069545A1 (es) * 2007-11-16 2010-02-03 Boehringer Ingelheim Pharma Derivados de aril y heteroarilcarbonilo de benzomorfanos y estructuras relacionadas, composiciones farmaceuticas que contienen dichos compuestos, obtencion de las mismas, su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa (hsd) 1 y
EP2252598A2 (en) 2008-02-11 2010-11-24 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2245014B1 (en) * 2008-02-12 2011-11-02 Boehringer Ingelheim International GmbH Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
WO2009102460A2 (en) 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5538356B2 (ja) 2008-03-18 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
MX2010011935A (es) 2008-05-01 2011-05-19 Vitae Pharmaceuticals Inc Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1.
WO2009134387A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2324017B1 (en) 2008-07-25 2014-12-31 Boehringer Ingelheim International GmbH INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
NZ590495A (en) 2008-07-25 2012-10-26 Vitae Pharmaceuticals Inc Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8057970B2 (en) 2008-09-01 2011-11-15 D2S, Inc. Method and system for forming circular patterns on a surface
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
TWI531571B (zh) * 2009-11-06 2016-05-01 維它藥物公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜芳基羰基衍生物
TWI537258B (zh) 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物

Also Published As

Publication number Publication date
CO6781480A2 (es) 2013-10-31
SI2635563T1 (sl) 2015-04-30
UA110807C2 (uk) 2016-02-25
DK2635563T3 (en) 2015-02-02
EP2635563A1 (en) 2013-09-11
CA2816136A1 (en) 2012-05-10
EA022406B1 (ru) 2015-12-30
KR20130119939A (ko) 2013-11-01
AP2013006902A0 (en) 2013-06-30
TN2012000117A1 (en) 2013-09-19
CL2013001221A1 (es) 2013-11-08
AU2011323164B2 (en) 2015-07-23
AP3521A (en) 2016-01-11
PH12013500879A1 (en) 2013-07-01
AU2011323164A1 (en) 2013-05-02
WO2012061708A1 (en) 2012-05-10
PT2635563E (pt) 2015-04-13
US9120769B2 (en) 2015-09-01
IL225647A0 (en) 2013-06-27
US20140249174A1 (en) 2014-09-04
CN103228642A (zh) 2013-07-31
AR083678A1 (es) 2013-03-13
JP2013541592A (ja) 2013-11-14
EA201390643A1 (ru) 2013-11-29
HK1184144A1 (en) 2014-01-17
US20120157488A1 (en) 2012-06-21
TWI537258B (zh) 2016-06-11
MX2013005069A (es) 2013-08-29
ES2533833T3 (es) 2015-04-15
SG189859A1 (en) 2013-06-28
GEP20166481B (en) 2016-05-25
NZ609281A (en) 2015-02-27
SMT201500095B (it) 2015-07-09
RS53900B1 (sr) 2015-08-31
EP2635563B1 (en) 2015-01-14
TW201242960A (en) 2012-11-01
HRP20150327T1 (hr) 2015-04-24
UY33701A (es) 2012-05-31
ECSP12011788A (es) 2012-10-30
ECSP13012664A (es) 2013-08-30
PL2635563T3 (pl) 2015-06-30
CY1116043T1 (el) 2017-01-25
BR112013011095A2 (pt) 2016-08-02
ME02066B (me) 2015-05-20
CN103228642B (zh) 2015-02-18
US8686149B2 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
PE20140123A1 (es) Formas cristalinas de la sal clorhidrato de (4a-r,9a-s)-1-(1h-benzoimidazol-5-carbonil)-2,3,4,4a,9,9a-hexahidro-1h-inden[2,1-b]piridin-6-carbonitrilo y su uso como inhibidores de hsd 1
PE20171255A1 (es) Forma cristalina y amorfa de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
CO6430432A2 (es) Cristales
BR112013002484A2 (pt) composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto.
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
BR112013000673A2 (pt) formas sólidas de romidepsina e seus usos
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
CO7400871A2 (es) Compuestos de piridilo sustituidos con heteroarilo útiles como moduladores de cinasa
MY165584A (en) Ampk-activating heterocyclic compounds and methods for using the same
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
EA201590748A1 (ru) Противовирусные соединения против rsv
IN2012DN00692A (es)
EA201270254A1 (ru) Производные 5-фторпиримидинона
PH12012502138B1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
MX2013008212A (es) Derivados de 7-azaindol.
BR112012030482A2 (pt) tratamento de diabetes tipo 2
MX2012001620A (es) Derivados de n1-acil-5-fluoropirimidinona.
UA113638C2 (xx) 4-(бензоімідазол-2-іл)-тіазольні сполуки та споріднені азапохідні
EA201491036A1 (ru) Производные 2-йодимидазола
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
BR112012027813A2 (pt) piperazinotriazinas como inibidores de pi3k para uso no tratamento de distúrbios antiproliferativos
MX2023004668A (es) Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico.
BR112013003740A2 (pt) composições algicidas sinergísticas incluindo derivados de hidrazona e cobre

Legal Events

Date Code Title Description
FD Application declared void or lapsed